


(Formerly Sree Rayalaseema Alkalies and Allied Chemicals Limited)
6-2-1012, 2nd Floor, TGV Mansion, Khairatabad, Hyderabad – 500 004,
Telangana, INDIA.



DNV-GL

REF:TGVSL:SECL:226BM:BSE:2021-22:

11th November, 2021

BSE LIMITED, PHIROZE JEEJEEBHOY TOWERS, 25th FLOOR, DALAL STREET, M U M B A I - 400 001

Phone: 022-22721233 / 34

Kind Attn: DCS - CRD

Dear Sir,

Sub: Outcome of the Board Meeting – Board approval for Un-audited financial results for the Second Quarter/Half Year Ended 30th September, 2021 – Reg.

Ref: 1. Regulation 30 and 33 of SEBI (LODR) Regulations, 2015.

2. Scrip Code: 507753.

Please find enclosed herewith a copy of Un-audited Financial Results for the Second Quarter/Half Year Ended 30th September, 2021 of TGV SRAAC LIMITED which has been taken on record by the Board of Directors in their Meeting held on 11th November, 2021 through Video Conference (VC). Also enclosed herewith other decisions taken by the Board.

- (1) Un-audited Financial Results for the Second Quarter/Half Year Ended 30th September, 2021 as per the Stock Exchange Format in compliance of Schedule-III and in pursuance to Regulation 33 of SEBI (LODR) Regulations, 2015 (Ind-AS).
- (2) Copy of Statutory Auditors Limited Review Report for the Second Quarter/Half Year Ended 30.09.2021 pursuance to Regulation 33 of SEBI (LODR) Regulations, 2015.
- (3) Upon the recommendation of Nomination and Remuneration Committee (dt.09.09.2021) the Board in its meeting held on 11/11/2021 has co-opted Ms. Sridevi Madati (DIN:02446610) as Additional Director in pursuance to Sec. 161 of the Act. Further, she is designated as Non-Executive Woman Independent Director for 3 years in pursuant to Sec.149 of the Companies Act, 2013 read with SEBI (LODR) Regulations, 2015 and subject to approval of shareholders in the AGM.

Brief particulars of the incumbent are annexed to this letter (Annexure - 1).

RADHAKRISHN Digitally signed RADHAKRISHNA A MURTHY WURTHY VEMULA Date: 2021.11.11

...2...

Regd. Off. & factory: Gondiparla, KURNOOL – 518 004. (A.P) INDIA. ☎ + 91 8518 280006, 7, 8 Fax: 08518-280098

Corporate Off: 40-304, 2nd Floor, K.J. Complex, Bhagya Nagar, KURNOOL – 518 004. (A.P) INDIA. ☎ 08518-221933, 221939 Fax: 08518-226973

Bellary Power Plant: P.D.Halli (Post), T Budehal Dist. Pin 583 138, ☎ (0839) 265239, 265085, Fax: 0839-265240

Chennai Off: New No. 100(old No.74) 1st Floor, Greenways Road, Extn. R.A. Puram, Chennai-600 028. ☎ 044-24611932, 11940 Fax: 044-24612553


Bangalore Off: 25, 1st Floor, Shankara Park Road, Shankarapuram, Bangalore – 560 004. ☎ 080 – 26520493, 5120493, Fax: 080 – 266523655

Mumbai Off: 302, Rishikesh Apt. 3rd Floor, Above Sapna Hotel, Opp: N.L. College, S.V. Road, Malad(west)Mumbai-400 064 Tele Fax: 022-28084481/82

Delhi Off: 72/75, 2nd Floor, Amnt Chamber, Scindia House, Janpat, Connaught Place, New Delhi-110 001 Tele Fax: +91-11-51513233



(Formerly Sree Rayalaseema Alkalies and Allied Chemicals Limited) 6-2-1012, 2nd Floor, TGV Mansion, Khairatabad, Hyderabad – 500 004, Telangana, INDIA.





:: 2 ::

(4) The Board on consideration of Audit Committee recommendation dt.11.11.2021 has given approval to the company for making an investment upto Rs.10 Crores in the Equity of M/s. Brilliant Bio Pharma Pvt Ltd., (CIN:U24100TG2010PTC067485) a Related Party (belonging to Promoters) in pursuance to Sec.186 of Companies Act, 2013.

The valuation of shares will be determined as per approved provisions and methodology provided in Companies Act and other related provisions.

Required particulars of proposed investment are given in Annexure -2.

Kindly take the same on record and acknowledge.

Thanking you,

Yours faithfully, For **TGV SRAAC Limited**

RADHAKRISHNA Digitally signed by RADHAKRISHNA MURTHY VEMULA Date: 2021.11.11 16:29:22 +05'30'

(V. Radhakrishna Murthy) Chief General Manager & Company Secretary

Encl: As above.



(formerly Sree Rayalaseema Alkalies and Allied Chemicals Ltd.) Registered Office - Gondiparla, Kurnool - 518 004 (A.P) CIN: L24110AP1981PLC003077, Web: www.tgvgroup.com

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED 30TH SEPTEMBER, 2021

							Rs. in Lakhs
Sl.		Quarter ended			Half Year ended		Year Ended
No.	Particulars	30-09-2021	30-06-2021	30-09-2020	30-09-2021	30-09-2020	31-03-2021
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
I	Revenue from operations	30,465	25,068	25,216	55,533	48,881	1,00,872
II	Other income	134	129	154	263	317	988
III	Total Income (I+II)	30,599	25,197	25,370	55,796	49,198	1,01,860
IV	EXPENSES						
	a) Cost of materials consumed	9,478	8,075	8,955	17,553	16,770	36,153
	b) Purchases of Stock-in-trade	436	-	43	436	43	43
	c) Changes in inventories of finished goods,	208	201	47	409	127	159
	work-in progress and stock in trade		201		""	1	107
	d) Employee benefits expense	1,393	1,301	1,204	2,694	2,396	4,817
	e) Finance Costs	1,071	923	1,028	1,994	1,988	3,937
	f) Depreciation and Amortisation expense	1,651	1,585	1,573	3,236	3,146	6,318
	g) Power and Fuel	9,706	7,847	7,451	17,553	1	
	h) Other expenses	4,342	3,692	3,527	8,034		14,950
	Total expenses (a to h)	28,285	23,624	23,828	51,909	46,678	96,973
V	Profit before exceptional items and tax (III-IV)	2,314	1,573	1,542	3,887	2,520	4,887
VI	Exceptional items						
VII	Profit before Tax (V-VI)	2,314	1,573	1,542	3,887	2,520	4,887
VIII	Tax expense					1	
	- Current Tax for the year	417	268	270	685	445	900
	- Deferred Tax	415	314	181	729	365	959
	- Earlier years Income Tax	5	0	-	5	; 	56
IX	Profit for the period from Continuing operations (VII-VIII)	1,477	991	1,091	2,468	1,710	2,972
х	Profit(Loss) from Discontinued operations	(18)	(24)	(19)	(42)	(37)	(77)
XI	Tax expense of Discontinued operations	(7	1 ' '		(15)		`
XII	Profit/(Loss) from Discontinued operations after Tax (X-XI)	1				1	(77)
хШ	Profit for the period (IX+XII)	1,465	976	1,072	2,441	1,673	2,895
XIV	Other Comprehensive Income (Net of Tax)	(79	1	1	1		1
XV	Total Comprehensive Income for the period (XIII+XIV)	1,386	1	1	1	1	1
	•	7,555]	,		
XVI	Earnings per Equity share(for continuing operations)	1.00					
	(a) Basic (Rs.)	1.38			1	l	1
	(b) Diluted (Rs.)	1.38	0.93	1.03	2.31	1.63	1 2.79
XVII	Earnings per Equity share(for Discontinuing operations)						
	(a) Basic (Rs.)	(0.01					
İ	(b) Diluted (Rs.)	(0.01	(0.01	(0.01	(0.02	(0.03	(0.07
XVII	Earnings per Equity share(for Continuing and Discontinuing operations)						
	(a) Basic (Rs.)	1.37	0.92	2 1.0	2 2.2	9 1.5	8 2.72
	(b) Diluted (Rs.)	1.37	0.92	2 1.0	2.2	9 1.5	8 2.72



AUDITED STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2021

(₹. in Lakhs)

			(V. III Dukits)
		AS AT	AS AT
	DADTICIII ADC	30-09-2021	31-03-2021
	PARTICULARS		
		AUDITED	AUDITED
	ASSETS		
1	Non-Current Assets	*	
	Property,Plant and equipment	87,012	75,580
	Right-to-use assets on lease	1,687	1,811
	Capital work-in-progress	6,250	12,509
	Investment properties	7	7
	Financial Assets		
	Investments	9,091	8,861
	Other financial assets	926	924
	Other non-current assets	466	2,159
2	Current Assets	100	
-	Inventories	10,381	11,608
	Financial assets	10,501	11,000
	Trade receivables	11,656	9,919
	Cash and cash equivalents	3,058	3,247
	Bank balances other than Cash and cash equivalents	6,669	7,394
	Other Financial assets	10,005	9,479
	Other current assets	1,950	1,792
	TOTAL ASSETS	1,49,158	1,45,290
ъ	EQUITY AND LIABILITIES		1
В	EQUITY AND LIABILITIES		Į
1	Equity	10.710	10.710
	Equity Share capital	10,713	10,713
_	Other equity	52,929	50,308
2	Liabilities		
	Non-Current liabilites		
	Financial liabilities		į.
	Borrowings	29,373	25,328
	Lease liabilities	1,765	1,847
	Other Financial liabilities	7,036	6,478
	Deferred Tax Liabilities (Net)	9,066	8,363
	Deferred Government grants	18	28
	Current Liabilities		
	Financial liabilities		
	Borrowings	19,040	19,373
	Trade and other payables		
	total outstanding dues of micro enterprises and small		
	enterprises	1,217	704
	total outstanding dues of creditors other than micro		1
	enterprises and small enterprises	4,282	6,910
	Lease liabilities	386	387
	Other financial liabilites	7,911	10,07
	Other current liabilites	4,941	4,42
	Provisions	121	. 3
	Current tax Liability(Net)	360	32
	TOTAL EQUITY AND LIABILITIES	1,49,158	1,45,29

	Half Yea	r ended
l .	As at 30th	As at 30th
Particulars	September,	September,
- 	2021	2020
Cash flow from operating activities		
Profit before tax from continuing operations	3,887.33	2,520.99
Profit/(loss) before tax from discontinued operations	(42.31)	(37.07)
Profit before tax	3,845.02	2,483.92
Adjustments to reconcile profit before tax to net cash flows:	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	_,
Depreciation and amortisation expenses	3,254.05	3,146.33
Interest income	(245.12)	(301.03)
Unrealized foreign exchange (gain)/loss	268.82	(40.01)
Dividend income on investments made	(0.02)	-
Interest expenses	1,855.39	1,832.47
Interset on lease liability	115.45	124.1379
Interest expense due to amortisation of financial liability & deferred sales tax	1 10.10	
	23.24	' 31.46
recognised		
Income due to deferred sales tax recognised & capital subsidy recognised	(10.29)	(15.52)
Operating profit before working capital changes	9,106.55	7,261.77
Working capital adjustments:		
(Decrease)/Increase in trade payables	(2,114.93)	1,685.99
(Decrease)/Increase in current financial liabilities	492.23	(902.89
(Decrease)/Increase in other current liabilities	517.96	572.46
(Decrease)/Increase in non-current financial liabilities	558.16	283.40
(Decrease)/Increase in short term provisions	13.23	20.60
(Increase)/Decrease in trade receivables	(1,741.21)	(1,485.07
(Increase)/Decrease in inventories	1,226.54	1,639.97
(Increase)/Decrease in other current financial assets	(376.85)	(104.20
(Increase)/Decrease in other current assets	(158.29)	(149.99
(Increase)/Decrease in non-current financial assets	(0.83)	
(Increase)/Decrease in non-current assets	1,692.34	(1,202.09
Cash generated from operating activities	9,214.90	7,934.95
Direct taxes paid (net)	(637.11)	(65.92
Net cash flow from operating activities (A)	8,577.79	7,869.03
Cash flows from investing activities		
Purchase of fixed assets, including CWIP	(8,302.19)	(2,949.84
Sales/(Purchase) of investment	(2,654.56)	1
Interest received	96.05	188.00
Dividend received	0.02	-
Deposits matured/(placed) during the year	906.99	948.05
Redemption/(Investment) of margin money deposit	(183.14)	1
Net cash flow from/ (used in) investing activities (B)	(10,136.82)	
Cash flows from financing activities		
Proceeds from equity (share warrant application/Call money)	_	1,486.27
Repayment of preference shares	(0.28)	
	(1,855.39)	1
Interest paid (Repayment)/Proceeds of long term borrowings	3,757.66	
		1
(Repayment)/Proceeds from short term borrowings	(333.35)	
Payment of lease liability	(198.50)	
Net cash flow from/ (used in) in financing activities (C)	1,370.14	(2,698.2
Net increase/(decrease) in cash and cash equivalents (A + B + C)	(188.88)	1,521.9
Cash and cash equivalents at the beginning of the year	3,246.95	1
Cash and cash equivalents at the end of the year	3,058.06	
		1
Components of cash and cash equivalents		
Cash on hand	11.52	7.9
Cheques on hand	-	-
Balances with banks		
- in Current Account	2,376.78	882.5
In Current recount		
Deposits with original maturity of less than three months	669.76	1,303.7

Reporting of segment wise Revenue, Results and Capital Employed under Regulation 33 of SEBI (LODR), Regulations, 2015 for the 1st Half Year/Quarter ended 30.09.2021

Rs. in Lakhs

SI.	Particulars	Quarter Ended			Half Year ended		Year Ended
No.		30-09-2021	30-06-2021	30-09-2020	30-09-2021	30-09-2020	31/03/2021
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
1	Segment Revenue						
	a) Chemicals	28,834	24,145	22,419	52,979	44,073	91,511
	b) Oils & Fats	2,314	1,808	4,075	4,122	7,097	13,805
	TOTAL	31,148	25,953	26,494	57,101	51,170	1,05,316
	Less: Inter segment revenue	683	885	1,278	1,568	2,289	4,444
	Revenue from Operations	30,465	25,068	25,216	55,533	48,881	1,00,872
2	Segment Results						
	Profit/(Loss) before tax and interest:			İ			
	a) Chemicals	3,420	2,629	2,606	6,049	4,460	9,005
	b) Oils & Fats	(161)	(252)	(178)	(413)	(253)	(738
	TOTAL	3,259	2,377	2,428	5,636	4,207	8,267
	Less: I) a)Interest Expenses	1,071	923	1,028	1,994	1,988	3,93
	b)Interest Income	(126)	(119)	(142)	(245)	(301)	(557
	II) Other un-allocable						
	Expenditure net off Income	-	-		-	1	-
	Total Profit before Tax from Continuing operations	2,314	1,573	1,542	3,887	2,520	4,88
	Less: Loss from Power Plant (discontinuing operations)	(18)	(24)	(19)	(42)	(37)	(77
	Total Profit before Tax including loss from discontinuing	2,296	1,549	1,523	3,845	2,483	4,81
	operations						
3	Segment Assets	'					
	a) Chemicals	1,33,137	1,34,164	1,18,906	1,33,137	1,18,906	1,25,47
	b) Oils & Fats	6,776	6,622	8,100	6,776	8,100	9,94
	c) Other-un allocable Assets	8,354	8,556	9,441	8,354	9,441	8,95
	d) Power Plant (Discontinuing operations)	891	901	935	891	935	5 91
	TOTAL	1,49,158	1,50,243	1,37,382	1,49,158	1,37,382	1,45,29
4	Segment Liabilities						
	a) Chemicals	77,908	78,796	70,051	77,908	3 70,051	75,52
	b) Oils & Fats	3,578	5,187	5,736	3,578	5,736	5,59
	c) Other –un allocable Liabilities	4,029	1	4,553			1
	d) Power Plant (Discontinuing operations)	-	_		-		
	TOTAL	85,515	87,986	80,340	85,51	5 80,34	84,26

NOTE:

- 1) The above un-audited financial results for the 1st Half Year/Quarter ended 30th September, 2021 were reviewed by the Audit Committee and approved by the Board of Directors at a meeting convened through other audio visual means. held on 11th November, 2021.
- 2) The statutory auditors have carried out Limited Review of the above financial results for the 1st Half Year/Quarter ended 30th September, 2021.
- 3) The figures for the corresponding previous year/ quarter have been restated/ regrouped and reclassified, wherever necessary to conform with the current year/ quarter presentation.

Place: Hyderabad

Date: 11th November,2021

By Order of the Board For TGV SRAAC LIMITED

(K,KARUNAKAR ŔAO) EXECUTIVE DIRECTOR & CEO

(DIN: 02031367)



K.S. RAO & Co

CHARTERED ACCOUNTANTS

Limited Review Report - Financial Results

To the Board of Directors of TGV SRAAC Limited,

 We have reviewed the accompanying Statement of Unaudited Financial Results of TGV SRAAC LIMITED ("the Company") for the Quarter and Half Year ended 30th September 2021 (the "statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the financial statement based on our review.

- 2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information performed by the Independent Auditor of the Entity, issued by Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free from material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) and other recognized accounting principles and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad

Date: 11th November 2021

firm's Regn No. 003105

for K S Rao & Co.
Chartered Accounta

(P. GOVARDHANA REDO


Partner

Membership No. 029193

UDIN 2 10 29193 AAAA NL 2142



(Formerly Sree Rayalaseema Alkalies and Allied Chemicals Limited)
6-2-1012, 2nd Floor, TGV Mansion, Khairatabad, Hyderabad – 500 004,
Telangana, INDIA.





ANNEXURE - 1

Brief Profile

(Details required in terms of SEBI Circular No. CIR/CFD/CMD/4/2015 dtd. 09/09/2015)

S. No.	Details of event that need to be provided	Information of such event(s)		
1.	Name	Ms. Sridevi Madati (DIN: 02446610)		
2.	Date of Birth	10-01-1977		
3.	Qualification	B.Com., LLB and MDBA, FCS		
4.	Reason for change viz., appointment, resignation, removal, death or otherwise	Appointment		
5.	Date of appointment & terms of appointment	The Board in its meeting held on 11/11/2021 has co-opted as Additional Director. Further, the Board designated her as Non-Executive Woman Independent Director for 3 years subject to shareholders approval in the AGM.		
6.	Brief profile (in case of appointment)	Ms. Sridevi Madati is a qualified Practicing Company Secretary having more than 17 years post qualification experience. She is also a qualified resolutional professional.		
7.	Details of previous employment	Starting her career with a Chartered Accountants Firm later joined Surana Group for a period of 6 years i.e., upto 2012 and now at present she is a practicing company secretary having more than 7 years experience.		
8.	Disclosure of relationships (in case of appointment of a Director)	She has not having relationship with the Directors and KMP of the Company.		
9.	Directorship in other companies	 Danlaw Technologies India Ltd. XEM Distributions Private Ltd. Maks Realtors Private Ltd. Sigachi Loboratories Ltd. 		

RADHAKRISHNA Digitally signed by RADHAKRISHNA MURTHY VEMULA VEMULA DINE: 2021.11.1116:29:39 +05'30'



(Formerly Sree Rayalaseema Alkalies and Allied Chemicals Limited) 6-2-1012, 2nd Floor, TGV Mansion, Khairatabad, Hyderabad – 500 004, Telangana, INDIA.

①040-23313842, Fax: 040-23313875 Email: sralkalies@tgvmail.net
CIN:L24110AP1981PLC003077



ANNEXURE - 2

- A. Details which a Listed Entity needs to disclose for the events that are deemed to be material as specified in Para A of Part A of Schedule III of Listing Regulations.
- 1. Acquisitions(s) (including agreement to acquire) of securities, Scheme of Arrangement (amalgamation / merger / demerger / restructuring), or sale or disposal of any unit(s), divisions(s) or subsidiary of the listed entity or any other restructuring:
- 1.1 Acquisition (including agreement to acquire) securities:

S. No.	Particulars in respect of the Event	Details / Information of the Event
01	Name of the Target Entity, details	M/s Brilliant Bio-Pharma Private Limited (BBPL)
	in brief such as size, turnover etc.;	Issued & Paid-up Capital Rs.7,30,04,870.
		Face Value: Rs.10/- per Equity Share
		Turnover: Rs. 66,74,62,964 (as on 31.03.2021)
02	Whether the acquisition would fall within related party transaction(s) and whether the Promoter /	Yes Promoters are having majority stake in the Target
	Promoter Group Companies have any interest in the entity being acquired? If yes, nature of	Company. Value of shares to be acquired will be determined
	interest and details thereof and whether the same is done at "arms length";	by following approved methodology in the Act.
03	Industry to which the entity being acquired belongs;	Veterinary Pharma & Wind Power Industry
04	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of Target Entity, if its business is outside the main line of business of the listed entity);	The Company intends to enter into the field of pharma in future for forward integration and value addition. By partnering with the already established M/s. BBPL, investee company will help the company to understand and make a step to focus on the pharma for future.
05	Brief details of any Governmental or Regulatory Approvals required for the acquisition;	No Government or Regulatory Approvals required.
06	Indicative time period for completion of the Acquisition ;	In the near future i.e., approximately one year.

RADHAKRISHNA Olgitally signed by RADHAKRISHRA MURTHY VEMULA Olme; 2021.11.11 16:2026 + 05:30

Regd. Off. & factory: Gondiparla, KURNOOL – 518 004. (A.P) INDIA. ★ + 91 8518 280006, 7, 8 Fax: 08518-280098

Corporate Off: 40-304, 2nd Floor, K.J. Complex, Bhagya Nagar, KURNOOL – 518 004. (A.P) INDIA.★ 08518-221933, 221939 Fax: 08518-226973

Bellary Power Plant: P.D.Halli (Post), T Budehal Dist. Pin 583 138, ★ (0839) 265239, 265085, Fax: 0839-265240

Chennai Off: New No. 100(old No.74) 1st Floor, Greenways Road, Extn. R.A. Puram, Chennai-600 028.★ 044-24611932, 11940 Fax: 044-24612553


Bangalore Off: 25, 1st Floor, Shankara Park Road, Shankarapuram, Bangalore – 560 004.★ 080 – 26520493, 5120493, Fax: 080 – 266523655

Mumbai Off: 302, Rishikesh Apt. 3rd Floor, Above Sapna Hotel, Opp: N.L. College, S.V. Road, Malad(west)Mumbai-400 064 Tele Fax: 022-28084481/82

Delhi Off: 72/75, 2nd Floor, Amnt Chamber, Scindia House, Janpat, Connaught Place, New Delhi-110 001 Tele Fax: +91-11-51513233



(Formerly Sree Rayalaseema Alkalies and Allied Chemicals Limited)
6-2-1012, 2nd Floor, TGV Mansion, Khairatabad, Hyderabad – 500 004,
Telangana, INDIA.





07		Cash consideration		
	cash consideration or share swap	· ·		
	and details of the same ;			
08	Cost of Acquisition of the price at	Rs.10.00 Cr.		
	which the shares are Acquired;			
		Price per Equity	Share will be determined as per	
		applicable rules,	statutory and relevant provisions	
		of the Act.		
09	Percentage of Shareholding /		ompany is not holding any shares	
1	Control Acquired and / or Number	in M/s.Brilliant	Bio-Pharma Private Limited	
	of Shares Acquired;	(BBPL).		
10	Brief background about the entity		io-Pharma Private Limited (BBPL)	
	acquired in terms of products /		100TG2010PTC067485 is Private	
	line of business acquired, Date of		ny incorporated on 11.03.2010	
1	Incorporation, History of Last 3		sions of companies Act, 1956 with	
ŀ	Years Turnover, Country in which			
	the acquired entity has presence	Khairatabad, Hyderabad - 500 004 (T.S).		
	and any other significant			
	information (in brief);	BBPL is a Veterinary Vaccines and animal health		
İ		products manufacturing company. Its Products are		
		being supplied within India and Abroad. The		
		details pf previous three years turnover as under :		
		Year Turnover		
			(Rs.in Lakhs)	
		2018-19	14996.43	
		2019-20	16556.37	
		2020-21	6674.62	
1				

Kindly take the same on record and acknowledge.

Thanking you,

Yours faithfully, For **TGV SRAAC Limited**

RADHAKRISHNA Digitally signed by RADHAKRISHNA MURTHY VEMULA DIRECTOR 1.11.11 1629-56 +05'30'

(V. Radhakrishna Murthy) Chief General Manager & Company Secretary